Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

J&J's Darzalex extends progression-free survival in late-state multiple myeloma study over Velcade/MP alone

Published 08/24/2017, 10:04 AM
© Reuters.  J&J's Darzalex extends progression-free survival in late-state multiple myeloma study over Velcade/MP alone
JNJ
-
GMAB
-
  • Preliminary results from a Phase 3 clinical trial, ALCYONE, assessing Johnson & Johnson unit (JNJ -0.3%) Janssen Biotech's DARZALEX (daratumumab), in combination with Takeda's VELCADE (bortezomib) and melphalan-prednisone, in treatment-naive multiple myeloma patients showed a statistically valid increase in progression-free survival (PFS) compared to Velcade and melphalan-prednisone (VMP) alone.
  • The pre-planned interim analysis showed the addition of DARZALEX reduced the risk of cancer progression or death by 50%. Median PFS in the DARZALEX group has not been reached. Median PFS in patients treated with VMP alone was estimated to be 18.1 months.
  • The Independent Data Monitoring Committee has recommended that the data be unblinded. All participants will continue to be followed for safety and overall survival. The data will be submitted for presentation at a future medical conference and for publication.
  • Janssen licensed daratumumab from Genmab A/S (OTCPK:GNMSF)(OTCPK:GMXAY) in 2012.
  • Genmab maintains its 2017 guidance.
  • Now read: The Top 5 Healthcare Dividend Stocks Today


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.